In Silico Characterization of Masitinib Interaction with SARS‐CoV‐2 Main Protease

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection continues to be a global health problem. Despite the current implementation of COVID‐19 vaccination schedules, identifying effective antiviral drug treatments for this disease continues to be a priority. A recent study showed that masitinib (MST), a tyrosine kinase inhibitor, blocks the proteolytic activity of SARS‐CoV‐2 main protease (Mpro). Although MST is a potential candidate for COVID‐19 treatment, a comprehensive analysis of its interaction with Mpro has not been done. In this work, we performed molecular dynamics simulations of the MST‐Mpro complex crystal structure. The effect of the protonation states of Mpro H163 residue and MST titratable groups were studied. Furthermore, we identified the MST substituents and Mpro mutations that affect the stability of the complex. Our results provide valuable insights into the design of new MST analogs as potential treatments for COVID‐19.

[1]  T. Bärnighausen,et al.  Climate and the spread of COVID-19 , 2021, Scientific Reports.

[2]  T. Jin,et al.  Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease , 2021, Frontiers in Chemistry.

[3]  A. Schiedel,et al.  Targeting the Main Protease of SARS‐CoV‐2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors , 2021, Angewandte Chemie.

[4]  S. Alcaro,et al.  Current Updates on Naturally Occurring Compounds Recognizing SARS-CoV-2 Druggable Targets , 2021, Molecules.

[5]  Aayush Gupta,et al.  Profiling SARS-CoV-2 Main Protease (MPRO) Binding to Repurposed Drugs Using Molecular Dynamics Simulations in Classical and Neural Network-Trained Force Fields , 2020, ACS combinatorial science.

[6]  R. Hilgenfeld,et al.  SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging , 2020, Nature Chemical Biology.

[7]  Rachel W. Martin,et al.  Sequence Characterization and Molecular Modeling of Clinically Relevant Variants of the SARS-CoV-2 Main Protease , 2020, Biochemistry.

[8]  Gennady M Verkhivker,et al.  Impact of Early Pandemic Stage Mutations on Molecular Dynamics of SARS-CoV-2 Mpro , 2020, J. Chem. Inf. Model..

[9]  K. Gajiwala,et al.  Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19 , 2020, Journal of medicinal chemistry.

[10]  D. Suárez,et al.  SARS-CoV-2 Main Protease: A Molecular Dynamics Study , 2020, J. Chem. Inf. Model..

[11]  Douglas E. V. Pires,et al.  mCSM-lig: quantifying the effects of mutations on protein-small molecule affinity in genetic disease and emergence of drug resistance , 2016, Scientific Reports.

[12]  Berk Hess,et al.  GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers , 2015 .

[13]  C. Simmerling,et al.  ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. , 2015, Journal of chemical theory and computation.

[14]  Douglas E. V. Pires,et al.  DUET: a server for predicting effects of mutations on protein stability using an integrated computational approach , 2014, Nucleic Acids Res..

[15]  James Andrew McCammon,et al.  Effects of histidine protonation and rotameric states on virtual screening of M. tuberculosis RmlC , 2013, Journal of Computer-Aided Molecular Design.

[16]  Matthew C. Swain.  Chemicalize.org , 2012, J. Chem. Inf. Model..

[17]  S. Bailey,et al.  ICAIS provides a unique forum for synthesizing knowledge of aquatic invasive species , 2021, Management of Biological Invasions.